Abstract
Background
Italy has been the first European country to be affected by the COVID-19 epidemic which started out at the end of February. In this report, we focus our attention on the Veneto Region, in the North-East of Italy, which is one of the areas that were first affected by the rapid spread of SARS-CoV-2. We aim to evaluate the trend of all-cause mortality and to give a description of the characteristics of the studied population.
Methods
Data used in the analyses were released by the majority of municipalities and cover the 93% of the total population living in the Veneto Region. We evaluated the trend of overall mortality from Jan.01 to Jun.30. 2020. Moreover we compared the COVID-19-related deaths to the overall deaths.
Results
From March 2020, the overall mortality rate increased exponentially, affecting males and people aged > 76 the most. The confirmed COVID-19-related death rate in the Veneto region between Mar.01 and Apr.302020 is 30 per 100,000 inhabitants. In contrast, the all-cause mortality increase registered in the same months in the municipalities included in the study is 219 per 100,000 inhabitants.
Conclusions
COVID-19 has a primary role in the increase in mortality but does not entirely explain such a high number of deaths. Strategies need to be developed to reduce this gap in case of future waves of the pandemic.
Keywords: COVID-19, Mortality, Italy, Public health burden
Background
At the end of February 2020, the first cases of SARS-CoV-2 infection were recorded in Northern Italy. From that moment, the curve of positive cases started growing exponentially [1].
The implemented policies brought to a progressive closure of all the non-essential activities that ultimately resulted in a state of full lockdown on Mar.08 in Northern Italy and on Mar.10 in the entire country.
Although the actions undertaken have shown to be effective in mitigating the progression of the epidemic [2], Italy appears to be the country with the highest proportion of severely ill patients requiring invasive ventilation and with the highest percentage of deaths [3, 4], with the health care system being heavily burdened by the strain of the current epidemic [5]. As observed elsewhere, studying the spread of the outbreak is challenging due to the high number of asymptomatic subjects [6]. In Italy, in addition, different testing policies were implemented across the Italian regions [7], introducing a critical detection bias. Indeed, in some areas only symptomatic/mild symptomatic subjects were tested, whereas in others an extensive testing strategy of both symptomatic and asymptomatic subjects was carried out [7].
Due to such limitations, an evident approach would be to consider overall mortality as a general proxy for the COVID-19 cause-specific deaths. Overall morality trends provide in general useful information [8] and are, more specifically, well-suited to describe epidemics [9–11].
The Veneto region, in Italy, has been one of the first areas to be affected by the SARS-CoV-2 outbreak, and the most aggressive in promoting early detection of cases via mass-screening [2]. In Veneto, COVID-19 cause-specific mortality rates were biased and likely underestimated. Indeed, COVID-19 was both the primary cause of death, but also it might have acted as a mediator, worsening pre-existing conditions, or it simply went undetected under particular circumstances.
In this work, we present estimates of mortality in the first months of the epidemics in a selected number of municipalities in the Veneto region, covering about 93% of the population. In the following section, we evaluate the trend of the overall mortality rate in the Veneto region for both the first semester of 2020 and the last 5 years, to understand the direction and magnitude of change in total mortality in this region and the consequent potential underestimation of the COVID-19 burden.
Materials and methods
Data
The Italian National Institute of Statistics (ISTAT) made available on its website the mortality data of 563 Veneto municipalities, with data updated to Jun.30 2020 [12].
The number of municipalities was not planned a priori but represents the number of municipalities that agreed to take part in the project. The municipalities included in the study cover 93% of the Veneto population (4,560,246 out of 4,907,704 total subjects) [12]. The reported characteristics of the subjects are class of age and sex of the deceased. No information is reported about the cause of death.
The number of COVID-19 attributable deaths per region was provided by the Italian Department of Civil Protection and was elaborated by the data warehouse at the University of Padova [13].
Statistical analysis
We evaluated the trend of the daily all-cause mortality rate in Veneto in the first 6 months of the last 6 years. The regression model for mortality used the observed time series, which was smoothed using local regression, with a smoothing parameter equal to 0.4. Feb.29 was excluded from the analysis.
The all-cause mortality rate for March–April 2019 and March–April 2020 and its change percentage (Mar.01 – Apr.30 2019 vs. Mar.01-Apr.30 2020) was also evaluated overall, by province (as the Veneto region is divided into provinces, in turn divided into municipalities) and by sex. The change percentage in mortality rate was evaluated using the following formula:
Moreover, all-causes mortality was evaluated in the region by class of age (0–64, 65–75, over 75 years) from Jan.01 to Jun.30 2020.
The COVID-19-related death rate from Mar.01 to Apr.30, when the infections first peaked, was calculated on the entire region per 100,000 inhabitants since COVID-19 data are provided only at the regional level. Moreover, we evaluated the change in mortality rate for March and April 2020 with respect to the average mortality rate for the same months of the last 5 years in the selected municipalities in order to understand if and how the COVID-19 mortality rate can explain the change in all-cause mortality rate.
All the analyses were performed using R 3.6.3 [14].
Results
Figure 1 compares the daily mortality rate in 2020 with the average daily mortality rate in the previous 5 years. In January and in the first half of February both values and trends are comparable. Nevertheless, starting from the beginning of March, there is a definite increase in the daily mortality rate in 2020. At the end of March the increase of daily mortality rate starts to slow down and from April the slope starts to decrease. (Fig. 1).
Fig. 1.
Daily mortality rate per 100,000 inhabitants for the first six months of 2020 and for the same period of the five previous years, obtained through the aggregation of selected municipalities of Veneto. The vertical line corresponds to the beginning of the lockdown
In all provinces, intended as the aggregation by province of the selected municipalities, the overall change from 2019 to 2020 of the mortality rate of March and April is positive, with males showing a higher increase (Table 1). The provinces that were most affected by this early stage of the outbreak are Treviso and Verona. The first case of COVID-19 in Veneto was reported in the province of Padova.
Table 1.
Mortality change rate from 2019 to 2020 in March and April. Mortality rate in males, females, and overall in 2019 and 2020 stratified by province resulting from the aggregation of selected municipalities
| Provinces | Males mortality ratea | Females mortality ratea | Total mortality ratea | Mortality rate variation (%) | |||||
|---|---|---|---|---|---|---|---|---|---|
| 2019 | 2020 | 2019 | 2020 | 2019 | 2020 | Males | Females | Total | |
| Verona | 1.51 | 2.30 | 1.66 | 2.38 | 1.59 | 2.34 | 51.73 | 42.91 | 47.02 |
| Vicenza | 1.51 | 2.01 | 1.56 | 2.01 | 1.53 | 2.01 | 33.01 | 28.92 | 30.90 |
| Belluno | 2.32 | 2.72 | 2.43 | 2.72 | 2.38 | 2.72 | 17.34 | 11.88 | 14.47 |
| Treviso | 1.46 | 2.08 | 1.53 | 2.07 | 1.50 | 2.08 | 42.56 | 35.69 | 38.99 |
| Venezia | 1.86 | 2.21 | 1.91 | 2.30 | 1.89 | 2.25 | 18.73 | 19.95 | 19.36 |
| Padova | 1.61 | 1.90 | 1.66 | 2.16 | 1.64 | 2.03 | 17.75 | 30.42 | 24.32 |
| Rovigo | 2.03 | 2.66 | 2.52 | 2.80 | 2.28 | 2.73 | 30.76 | 11.15 | 19.63 |
a × 1000 inhabitants
Figure 2 shows a significant increase in mortality in people over 76 years starting from March, whereas, for people under 65 years old, there is no significant change. The class represented by people from 66 to 75 years old, shows a small increase in the number of deaths, also starting in March.
Fig. 2.
Number of deaths in the Veneto Region resulting from the aggregation of municipalities included in the study from Jan.01 2020 to Jun.30 2020 stratified by classes of age
The confirmed COVID-19-related death rate in the Veneto region between Mar.01 and Apr.30 is 30 per 100,000 inhabitants, whereas, for the municipalities included in the study, the all-cause mortality registered in the same months of 2020 is 219 per 100,000 inhabitants. The average mortality of the five previous years was 173 per 100,000 inhabitants. When adding the COVID-19 mortality to the average mortality of 2015–2019 (203 per 100,000 inhabitants), a 15 per 100,000 inhabitants’ deaths remain unexplained.
Discussion
The results of this study show an association between COVID-19 and an increase in all-cause mortality in the municipalities of Veneto included in the study.
The Veneto region was the second Italian region to detect COVID-19 positive patients and rapidly responded by introducing restrictive measures to try to reduce the spread of the virus: regional authorities imposed an immediate lockdown to Vo’ [15], the municipality where the first cases were detected; a strong swab campaign, on both symptomatic and asymptomatic individuals, was set up [7]; the use of masks was set as mandatory outdoors as well as indoors. Veneto has been largely studied for the good results obtained in both reducing the spread of the virus and the management of COVID-19 patients [16, 17]. It is indeed interesting to evaluate the trend of mortality (both COVID-19 mortality and all-cause mortality) in a region that was at the forefront of the battle against the virus.
The large increase in the number of positive cases and, consequently, in the number of deaths has been so fast that it can be easily detected as soon as a few days after the identification of the first case [1].
The trend of the daily mortality rate in 2020 seems regular until the end of February and then it suddenly starts to increase rapidly. Comparing this curve with the one given by the average of the 5 previous years, we can notice that the two curves take clearly separate paths starting from March.
In the previous years, the mortality rate starts to slowly decrease from March, whereas in 2020, the trend is the opposite. This change in trend corresponds to the beginning of the COVID-19 outbreak.
Effects of the decree that placed the Veneto Region on lockdown as of Mar 08 start showing after a couple of weeks. Indeed, the daily mortality rate tends to stabilize and then to decrease. The incubation period together with the days from symptoms onset to death could explain this delay in the decrease of the mortality rate [18].
Focusing on 2020, we notice unchanged mortality for people under 65, whereas an increase in the number of deaths in March is evident for 66–75 years older adults and even more for subjects over 65. Usually, the number of deaths in Italy over 65 tends to gradually decrease from the second half of February [19]. However, here the contribution of COVID-19 in increasing the mortality in older people appears evident, and this agrees well with what has already been published [4, 20].
For what concerns gender distribution, males seem to be more prone to death than women. This appears evident for five provinces out of seven and once again agrees with previous studies [4, 21].
The heterogeneity in the mortality rate change observed between the different provinces could be due to many factors, such as: the different healthcare policies adopted; the different geographical accessibility and successibility to the pandemic exposure; the different number of of nursing houses that were highly affected by the pandemic.
The 2020 increase in the death rate in March and April (46 × 100,000) is only partially explained by COVID-19 death rate (30 × 100,000) of the same months, one-third of the deaths remain unexplained.
It is worth pointing out that we analyzed all-cause mortality and not cause-specific mortality. It is likely that the excess of mortality detected is attributable mainly to SARS-CoV-2 infection, including both COVID-19 official deaths and undiagnosed COVID-19 deaths. However, we cannot rule out that such excess of deaths is not directly related to the SARS-CoV-2 infection. As an example, it has been detected a reduction of acute coronary syndrome (ACS) cases referred to the emergency departments after the beginning of the outbreak [22]. Such reduction would be attributable to not only an actual reduction of ACSs, but also to the fear of contamination, which makes people in need of health care more reluctant to visit the hospital, and to the difficulties in accessing healthcare. A survey conducted across the six continents (with America divided into Northern and Southern) just highlighted that issue by showing a delay in time to admission of STEMI patients (ST-elevation myocardial infarction) in countries with full lockdown, the same that was imposed in the Veneto region [23]. Together with these difficulties in accessing the healthcare system, increased systemic inflammation has been observed in subjects undergoing routine hematology tests during the lockdown [24]. The combination of all these psychological and pathological aspects could play a role in the increase in mortality observed. The experience gained during the first wave of COVID-19 will be useful to be ready for future waves of the pandemic.
Study limitations
ISTAT only provides the number of all-cause deaths and the number of residents. This reflects in the modeling approach, which considers only gross mortality rates since no information is available about the primary cause of death or about the possible drug therapy subjects are undergoing or other personal characteristics. Moreover, data on COVID-19 related deaths did not include subjects’ characteristics, thus not allowing the comparison with overall mortality by age group or sex.
Conclusions
The current data show increased mortality in older people and a greater change in mortality in male subjects. The curve of observed mortality slowed down starting from April, proving that the lockdown measures worked, but the number of COVID-19 deaths in Veneto does not seem to match the real amount of subjects that have died in the municipalities included in the study. If such data is confirmed, it will become clear that the COVID-19 outbreak public health burden is even worse than expected because it would be associated with an excess of mortality not directly related to the infection.
Continuous surveillance, enforced in every municipality, must be conducted in the coming weeks to evaluate the trend of COVID-19, improve knowledge on this matter, and act conscientiously.
Acknowledgments
Not applicable
Abbreviations
- SARS-CoV-2
Severe acute respiratory syndrome - coronavirus - 2
- COVID-19
Coronavirus disease 2019
- ISTAT
Italian national institute of statistics
- ACS
Acute coronary syndrome
- STEMI
ST-elevation myocardial infraction
Authors’ contributions
EG and DG conceptualized the study, EG and IP designed the work and conducted the analyses, DA and CL contributed to the interpretation of data, EG and GL drafted the work, PB, ASA and DG critically revised the work. All authors read and approved the final manuscript.
Funding
None
Availability of data and materials
The public access to the databases is open. The datasets generated and analysed during the current study are available in the mortality_veneto repository, https://github.com/UBESP-DCTV/mortality_veneto. The datasets can be found as .rds files in the raw-data folder of the repository, https://github.com/UBESP-DCTV/mortality_veneto/tree/master/raw-data
Declarations
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Elisa Gallo, Email: elisa.gallo@unipd.it.
Ilaria Prosepe, Email: ilaria.prosepe@studenti.unipd.it.
Giulia Lorenzoni, Email: giulia.lorenzoni@unipd.it.
Aslihan Şentürk Acar, Email: aslihans@hacettepe.edu.tr.
Corrado Lanera, Email: corrado.lanera@unipd.it.
Paola Berchialla, Email: paola.berchialla@unito.it.
Danila Azzolina, Email: danila.azzolina@uniupo.it.
Dario Gregori, Email: dario.gregori@unipd.it.
References
- 1.Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020;323(14):1335. doi: 10.1001/jama.2020.4344. [DOI] [PubMed] [Google Scholar]
- 2.Gregori D, Azzolina D, Lanera C, Prosepe I, Destro N, Lorenzoni G, Berchialla P. A first estimation of the impact of public health actions against COVID-19 in Veneto (Italy) J Epidemiol Community Health. 2020;74(10):858–860. doi: 10.1136/jech-2020-214209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA. 2020;323(16):1545–6. 10.1001/jama.2020.4031. [DOI] [PubMed]
- 4.Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. 10.1001/jama.2020.4683. [DOI] [PubMed]
- 5.Armocida B, Formenti B, Ussai S, Palestra F, Missoni E. The Italian health system and the COVID-19 challenge. Lancet Public Health 2020;0. doi:10.1016/S2468-2667(20)30074-8, 5, 5, e253. [DOI] [PMC free article] [PubMed]
- 6.COVID-19: What proportion are asymptomatic? CEBM. 2020 https://www.cebm.net/covid-19/covid-19-what-proportion-are-asymptomatic/. Accessed 11 Apr 2020.
- 7.Lorenzoni G, Lanera C, Azzolina D, Berchialla P, Gregori D, Gregori D, et al. Is a more aggressive COVID-19 case detection approach mitigating the burden on ICUs? Some reflections from Italy. Crit Care. 2020;24:175. doi: 10.1186/s13054-020-02881-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, Casey DC, Charlson FJ, Chen AZ, Coates MM, Coggeshall M, Dandona L, Dicker DJ, Erskine HE, Ferrari AJ, Fitzmaurice C, Foreman K, Forouzanfar MH, Fraser MS, Fullman N, Gething PW, Goldberg EM, Graetz N, Haagsma JA, Hay SI, Huynh C, Johnson CO, Kassebaum NJ, Kinfu Y, Kulikoff XR, Kutz M, Kyu HH, Larson HJ, Leung J, Liang X, Lim SS, Lind M, Lozano R, Marquez N, Mensah GA, Mikesell J, Mokdad AH, Mooney MD, Nguyen G, Nsoesie E, Pigott DM, Pinho C, Roth GA, Salomon JA, Sandar L, Silpakit N, Sligar A, Sorensen RJD, Stanaway J, Steiner C, Teeple S, Thomas BA, Troeger C, VanderZanden A, Vollset SE, Wanga V, Whiteford HA, Wolock T, Zoeckler L, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, Abreu DMX, Abu-Raddad LJ, Abyu GY, Achoki T, Adelekan AL, Ademi Z, Adou AK, Adsuar JC, Afanvi KA, Afshin A, Agardh EE, Agarwal A, Agrawal A, Kiadaliri AA, Ajala ON, Akanda AS, Akinyemi RO, Akinyemiju TF, Akseer N, Lami FHA, Alabed S, al-Aly Z, Alam K, Alam NKM, Alasfoor D, Aldhahri SF, Aldridge RW, Alegretti MA, Aleman AV, Alemu ZA, Alexander LT, Alhabib S, Ali R, Alkerwi A', Alla F, Allebeck P, al-Raddadi R, Alsharif U, Altirkawi KA, Martin EA, Alvis-Guzman N, Amare AT, Amegah AK, Ameh EA, Amini H, Ammar W, Amrock SM, Andersen HH, Anderson BO, Anderson GM, Antonio CAT, Aregay AF, Ärnlöv J, Arsenijevic VSA, Artaman A, Asayesh H, Asghar RJ, Atique S, Avokpaho EFGA, Awasthi A, Azzopardi P, Bacha U, Badawi A, Bahit MC, Balakrishnan K, Banerjee A, Barac A, Barker-Collo SL, Bärnighausen T, Barregard L, Barrero LH, Basu A, Basu S, Bayou YT, Bazargan-Hejazi S, Beardsley J, Bedi N, Beghi E, Belay HA, Bell B, Bell ML, Bello AK, Bennett DA, Bensenor IM, Berhane A, Bernabé E, Betsu BD, Beyene AS, Bhala N, Bhalla A, Biadgilign S, Bikbov B, Abdulhak AAB, Biroscak BJ, Biryukov S, Bjertness E, Blore JD, Blosser CD, Bohensky MA, Borschmann R, Bose D, Bourne RRA, Brainin M, Brayne CEG, Brazinova A, Breitborde NJK, Brenner H, Brewer JD, Brown A, Brown J, Brugha TS, Buckle GC, Butt ZA, Calabria B, Campos-Nonato IR, Campuzano JC, Carapetis JR, Cárdenas R, Carpenter DO, Carrero JJ, Castañeda-Orjuela CA, Rivas JC, Catalá-López F, Cavalleri F, Cercy K, Cerda J, Chen W, Chew A, Chiang PPC, Chibalabala M, Chibueze CE, Chimed-Ochir O, Chisumpa VH, Choi JYJ, Chowdhury R, Christensen H, Christopher DJ, Ciobanu LG, Cirillo M, Cohen AJ, Colistro V, Colomar M, Colquhoun SM, Cooper C, Cooper LT, Cortinovis M, Cowie BC, Crump JA, Damsere-Derry J, Danawi H, Dandona R, Daoud F, Darby SC, Dargan PI, das Neves J, Davey G, Davis AC, Davitoiu DV, de Castro EF, de Jager P, Leo DD, Degenhardt L, Dellavalle RP, Deribe K, Deribew A, Dharmaratne SD, Dhillon PK, Diaz-Torné C, Ding EL, dos Santos KPB, Dossou E, Driscoll TR, Duan L, Dubey M, Duncan BB, Ellenbogen RG, Ellingsen CL, Elyazar I, Endries AY, Ermakov SP, Eshrati B, Esteghamati A, Estep K, Faghmous IDA, Fahimi S, Faraon EJA, Farid TA, Farinha CSS, Faro A, Farvid MS, Farzadfar F, Feigin VL, Fereshtehnejad SM, Fernandes JG, Fernandes JC, Fischer F, Fitchett JRA, Flaxman A, Foigt N, Fowkes FGR, Franca EB, Franklin RC, Friedman J, Frostad J, Fürst T, Futran ND, Gall SL, Gambashidze K, Gamkrelidze A, Ganguly P, Gankpé FG, Gebre T, Gebrehiwot TT, Gebremedhin AT, Gebru AA, Geleijnse JM, Gessner BD, Ghoshal AG, Gibney KB, Gillum RF, Gilmour S, Giref AZ, Giroud M, Gishu MD, Giussani G, Glaser E, Godwin WW, Gomez-Dantes H, Gona P, Goodridge A, Gopalani SV, Gosselin RA, Gotay CC, Goto A, Gouda HN, Greaves F, Gugnani HC, Gupta R, Gupta R, Gupta V, Gutiérrez RA, Hafezi-Nejad N, Haile D, Hailu AD, Hailu GB, Halasa YA, Hamadeh RR, Hamidi S, Hancock J, Handal AJ, Hankey GJ, Hao Y, Harb HL, Harikrishnan S, Haro JM, Havmoeller R, Heckbert SR, Heredia-Pi IB, Heydarpour P, Hilderink HBM, Hoek HW, Hogg RS, Horino M, Horita N, Hosgood HD, Hotez PJ, Hoy DG, Hsairi M, Htet AS, Htike MMT, Hu G, Huang C, Huang H, Huiart L, Husseini A, Huybrechts I, Huynh G, Iburg KM, Innos K, Inoue M, Iyer VJ, Jacobs TA, Jacobsen KH, Jahanmehr N, Jakovljevic MB, James P, Javanbakht M, Jayaraman SP, Jayatilleke AU, Jeemon P, Jensen PN, Jha V, Jiang G, Jiang Y, Jibat T, Jimenez-Corona A, Jonas JB, Joshi TK, Kabir Z, Kamal R, Kan H, Kant S, Karch A, Karema CK, Karimkhani C, Karletsos D, Karthikeyan G, Kasaeian A, Katibeh M, Kaul A, Kawakami N, Kayibanda JF, Keiyoro PN, Kemmer L, Kemp AH, Kengne AP, Keren A, Kereselidze M, Kesavachandran CN, Khader YS, Khalil IA, Khan AR, Khan EA, Khang YH, Khera S, Khoja TAM, Kieling C, Kim D, Kim YJ, Kissela BM, Kissoon N, Knibbs LD, Knudsen AK, Kokubo Y, Kolte D, Kopec JA, Kosen S, Koul PA, Koyanagi A, Krog NH, Defo BK, Bicer BK, Kudom AA, Kuipers EJ, Kulkarni VS, Kumar GA, Kwan GF, Lal A, Lal DK, Lalloo R, Lallukka T, Lam H, Lam JO, Langan SM, Lansingh VC, Larsson A, Laryea DO, Latif AA, Lawrynowicz AEB, Leigh J, Levi M, Li Y, Lindsay MP, Lipshultz SE, Liu PY, Liu S, Liu Y, Lo LT, Logroscino G, Lotufo PA, Lucas RM, Lunevicius R, Lyons RA, Ma S, Machado VMP, Mackay MT, MacLachlan JH, Razek HMAE, Magdy M, Razek AE, Majdan M, Majeed A, Malekzadeh R, Manamo WAA, Mandisarisa J, Mangalam S, Mapoma CC, Marcenes W, Margolis DJ, Martin GR, Martinez-Raga J, Marzan MB, Masiye F, Mason-Jones AJ, Massano J, Matzopoulos R, Mayosi BM, McGarvey ST, McGrath JJ, McKee M, McMahon BJ, Meaney PA, Mehari A, Mehndiratta MM, Mejia-Rodriguez F, Mekonnen AB, Melaku YA, Memiah P, Memish ZA, Mendoza W, Meretoja A, Meretoja TJ, Mhimbira FA, Micha R, Millear A, Miller TR, Mirarefin M, Misganaw A, Mock CN, Mohammad KA, Mohammadi A, Mohammed S, Mohan V, Mola GLD, Monasta L, Hernandez JCM, Montero P, Montico M, Montine TJ, Moradi-Lakeh M, Morawska L, Morgan K, Mori R, Mozaffarian D, Mueller UO, Murthy GVS, Murthy S, Musa KI, Nachega JB, Nagel G, Naidoo KS, Naik N, Naldi L, Nangia V, Nash D, Nejjari C, Neupane S, Newton CR, Newton JN, Ng M, Ngalesoni FN, de Dieu Ngirabega J, Nguyen QL, Nisar MI, Pete PMN, Nomura M, Norheim OF, Norman PE, Norrving B, Nyakarahuka L, Ogbo FA, Ohkubo T, Ojelabi FA, Olivares PR, Olusanya BO, Olusanya JO, Opio JN, Oren E, Ortiz A, Osman M, Ota E, Ozdemir R, PA M, Pain A, Pandian JD, Pant PR, Papachristou C, Park EK, Park JH, Parry CD, Parsaeian M, Caicedo AJP, Patten SB, Patton GC, Paul VK, Pearce N, Pedro JM, Stokic LP, Pereira DM, Perico N, Pesudovs K, Petzold M, Phillips MR, Piel FB, Pillay JD, Plass D, Platts-Mills JA, Polinder S, Pope CA, Popova S, Poulton RG, Pourmalek F, Prabhakaran D, Qorbani M, Quame-Amaglo J, Quistberg DA, Rafay A, Rahimi K, Rahimi-Movaghar V, Rahman M, Rahman MHU, Rahman SU, Rai RK, Rajavi Z, Rajsic S, Raju M, Rakovac I, Rana SM, Ranabhat CL, Rangaswamy T, Rao P, Rao SR, Refaat AH, Rehm J, Reitsma MB, Remuzzi G, Resnikoff S, Ribeiro AL, Ricci S, Blancas MJR, Roberts B, Roca A, Rojas-Rueda D, Ronfani L, Roshandel G, Rothenbacher D, Roy A, Roy NK, Ruhago GM, Sagar R, Saha S, Sahathevan R, Saleh MM, Sanabria JR, Sanchez-Niño MD, Sanchez-Riera L, Santos IS, Sarmiento-Suarez R, Sartorius B, Satpathy M, Savic M, Sawhney M, Schaub MP, Schmidt MI, Schneider IJC, Schöttker B, Schutte AE, Schwebel DC, Seedat S, Sepanlou SG, Servan-Mori EE, Shackelford KA, Shaddick G, Shaheen A, Shahraz S, Shaikh MA, Shakh-Nazarova M, Sharma R, She J, Sheikhbahaei S, Shen J, Shen Z, Shepard DS, Sheth KN, Shetty BP, Shi P, Shibuya K, Shin MJ, Shiri R, Shiue I, Shrime MG, Sigfusdottir ID, Silberberg DH, Silva DAS, Silveira DGA, Silverberg JI, Simard EP, Singh A, Singh GM, Singh JA, Singh OP, Singh PK, Singh V, Soneji S, Søreide K, Soriano JB, Sposato LA, Sreeramareddy CT, Stathopoulou V, Stein DJ, Stein MB, Stranges S, Stroumpoulis K, Sunguya BF, Sur P, Swaminathan S, Sykes BL, Szoeke CEI, Tabarés-Seisdedos R, Tabb KM, Takahashi K, Takala JS, Talongwa RT, Tandon N, Tavakkoli M, Taye B, Taylor HR, Ao BJT, Tedla BA, Tefera WM, Have MT, Terkawi AS, Tesfay FH, Tessema GA, Thomson AJ, Thorne-Lyman AL, Thrift AG, Thurston GD, Tillmann T, Tirschwell DL, Tonelli M, Topor-Madry R, Topouzis F, Towbin JA, Traebert J, Tran BX, Truelsen T, Trujillo U, Tura AK, Tuzcu EM, Uchendu US, Ukwaja KN, Undurraga EA, Uthman OA, Dingenen RV, van Donkelaar A, Vasankari T, Vasconcelos AMN, Venketasubramanian N, Vidavalur R, Vijayakumar L, Villalpando S, Violante FS, Vlassov VV, Wagner JA, Wagner GR, Wallin MT, Wang L, Watkins DA, Weichenthal S, Weiderpass E, Weintraub RG, Werdecker A, Westerman R, White RA, Wijeratne T, Wilkinson JD, Williams HC, Wiysonge CS, Woldeyohannes SM, Wolfe CDA, Won S, Wong JQ, Woolf AD, Xavier D, Xiao Q, Xu G, Yakob B, Yalew AZ, Yan LL, Yano Y, Yaseri M, Ye P, Yebyo HG, Yip P, Yirsaw BD, Yonemoto N, Yonga G, Younis MZ, Yu S, Zaidi Z, Zaki MES, Zannad F, Zavala DE, Zeeb H, Zeleke BM, Zhang H, Zodpey S, Zonies D, Zuhlke LJ, Vos T, Lopez AD, Murray CJL. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1459–1544. doi: 10.1016/S0140-6736(16)31012-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Alling DW, Blackwelder WC, Stuart-Harris CH. A study of excess mortality during influenza epidemics in the United States, 1968–1976. Am J Epidemiol. 1981;113(1):30–43. doi: 10.1093/oxfordjournals.aje.a113063. [DOI] [PubMed] [Google Scholar]
- 10.Hwang SW, Cheung AM, Moineddin R, Bell CM. Population mortality during the outbreak of severe acute respiratory syndrome in Toronto. BMC Public Health. 2007;7(1):93. doi: 10.1186/1471-2458-7-93. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Goldstein JR, Lee RD. Demographic perspectives on mortality of Covid-19 and other epidemics. Working Paper. Natl Bur Econ Res. 2020. 10.3386/w27043.
- 12.Decessi e cause di morte: cosa produce l’Istat. 2020. https://www.istat.it/it/archivio/240401. Accessed 6 Oct 2020.
- 13.Lanera C, Prosepe I, Berchialla P, Azzolina D, Lorenzoni G, Gregori D. covid19ita. 2020. https://r-ubesp.dctv.unipd.it/shiny/covid19ita/. Accessed 2 Apr 2020.
- 14.R Core Team . R: A language and environment for statistical computing. Vienna, Austria: R Foundation for statistical Computing; 2019. [Google Scholar]
- 15.Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo. Nature. 2020;584(7821):425–429. doi: 10.1038/s41586-020-2488-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Cavarretta E, Biondi-Zoccai G, Frati G, Versaci F. Veneto’s successful lesson for a world shocked by COVID-19: think globally and act locally. J Cardiothorac Vasc Anesth. 2020;34(9):2346–2348. doi: 10.1053/j.jvca.2020.06.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Mugnai G, Bilato C. Covid-19 in Italy: lesson from the Veneto region. Eur J Intern Med. 2020;77:161–162. doi: 10.1016/j.ejim.2020.05.039. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–582. doi: 10.7326/M20-0504. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Salute M della. Sistema di sorveglianza mortalità giornaliera. 2020. http://www.salute.gov.it/portale/caldo/dettaglioContenutiCaldo.jsp?lingua=italiano&id=4547&area=emergenzaCaldo&menu=vuoto. Accessed 11 Apr 2020.
- 20.Magnani C, Azzolina D, Gallo E, Ferrante D, Gregori D. How large was the mortality increase directly and indirectly caused by the COVID-19 epidemic? An analysis on all-causes mortality data in Italy. Int J Environ Res Public Health. 2020;17:3452. doi: 10.3390/ijerph17103452. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Azzolina D, Magnani C, Gallo E, Ferrante D, Gregori D. Gender and age factors affecting the mortality during the COVID-19 epidemic in Italy. Epidemiol Prev. 2020;44:252–9. 10.19191/EP20.5-6.S2.125. [DOI] [PubMed]
- 22.Metzler B, Siostrzonek P, Binder RK, Bauer A, Reinstadler SJ. Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage. Eur Heart J. 2020;41(19):1852–1853. doi: 10.1093/eurheartj/ehaa314. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Pessoa-Amorim G, Camm CF, Gajendragadkar P, De Maria GL, Arsac C, Laroche C, et al. Admission of patients with STEMI since the outbreak of the COVID-19 pandemic: a survey by the European society of cardiology. Eur Heart J Qual Care Clin Outcomes. 2020;6. 10.1093/ehjqcco/qcaa046. [DOI] [PMC free article] [PubMed]
- 24.Tona F, Plebani M, Gregori D, Carretta G, Lorenzoni G, Donato D, et al. “Stay home stay safe?” Systemic inflammation in subjects undergoing routine hematology tests during the lockdown period of COVID-19. Clin Chem Lab Med. 2020;1 ahead-of-print. 10.1515/cclm-2020-1016. [DOI] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The public access to the databases is open. The datasets generated and analysed during the current study are available in the mortality_veneto repository, https://github.com/UBESP-DCTV/mortality_veneto. The datasets can be found as .rds files in the raw-data folder of the repository, https://github.com/UBESP-DCTV/mortality_veneto/tree/master/raw-data


